Colorectal Cancer (CRC) Cell Models for Research

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related death, with over 1.9 million new cases and 930,000 deaths in 2020 (WHO GLOBOCAN). The lifetime risk of developing CRC is about 4.3% in men and 4.0% in women (NCI SEER). Five-year survival rates vary dramatically by stage: localized CRC has a 91% survival rate, regional CRC 72%, and distant metastatic CRC only 15% (NCI SEER). Key risk factors include age, inflammatory bowel disease, family history, and lifestyle factors such as diet, obesity, and smoking. The high mortality in metastatic disease underscores the urgent need for better therapeutic targets and predictive biomarkers.

CRC is an ideal model for mechanistic studies due to its well-characterized molecular subtypes (CMS1-4), extensive public genomic datasets (TCGA, COSMIC), and the availability of numerous cell lines representing different genetic backgrounds. Open questions remain regarding drug resistance mechanisms, tumor heterogeneity, and the role of the tumor microenvironment. Gene-edited cell models enable precise dissection of oncogenic drivers and tumor suppressor genes, facilitating functional validation and drug discovery.

CRC develops through distinct pathways:

1. Chromosomal Instability (CIN) Pathway: Accounts for ~85% of sporadic CRC. Involves stepwise accumulation of mutations in APC, KRAS, TP53, and loss of 18q.

2. Microsatellite Instability (MSI) Pathway: Due to defective DNA mismatch repair (MMR), leading to high mutation rates in repetitive sequences. Accounts for ~15% of sporadic CRC and most Lynch syndrome cases.

3. CpG Island Methylator Phenotype (CIMP) Pathway: Hypermethylation of promoter regions silences tumor suppressor genes, often associated with BRAF mutations and MSI.

4. Serrated Pathway: Characterized by BRAF mutations and CIMP, leading to serrated adenomas and MSI-high tumors.

Data from TCGA PanCancer Atlas and COSMIC.

Key signaling networks in CRC:

• • Wnt/β-catenin pathway: APC loss leads to β-catenin stabilization and transcription of MYC, CCND1.
• • MAPK/ERK pathway: KRAS/BRAF mutations drive constitutive signaling, promoting proliferation and survival.
• • PI3K/AKT/mTOR pathway: PIK3CA mutations activate downstream survival signals.
• • TGF-β pathway: SMAD4 loss impairs growth inhibition.
• • p53 pathway: TP53 mutations disrupt cell cycle arrest and apoptosis.
• • Notch and Hedgehog pathways also contribute to stemness and differentiation.

Organoids derived from patient tumors preserve 3D architecture and genetic heterogeneity, making them valuable for drug testing and personalized medicine approaches.

• • Patient-Derived Xenografts (PDX): Implantation of patient tumor fragments into immunodeficient mice; preserves tumor heterogeneity and drug response.
• • Genetically Engineered Mouse Models (GEMM): Conditional knock-in of KRAS G12D and APC loss (e.g., Villin-Cre; APCfl/fl; KRASLSL-G12D) recapitulates intestinal tumorigenesis.
• • Chemically Induced Models: Azoxymethane (AOM) combined with dextran sulfate sodium (DSS) induces colitis-associated CRC.
• • Orthotopic models: Injection of CRC cells into the cecal wall to mimic metastatic spread.

CRISPR-Cas9 gene editing enables the generation of isogenic cell lines with precise knockout, knock-in, or point mutations. These models are essential for studying the functional consequences of specific genetic alterations in a controlled background. Examples include:

• • TP53 knockout in HCT116 or RKO cells to study p53 loss-of-function.
• • KRAS G12D knock-in in wild-type KRAS cell lines (e.g., Caco-2) to model oncogenic activation.
• • APC truncation knock-in to recreate the most common APC mutation.
• • Reporter lines (e.g., GFP-tagged proteins) for live-cell imaging.

Commercially available, sequence-verified gene-edited models accelerate research by providing reproducible and validated tools. These models are generated using CRISPR/Cas9 technology and are available from various commercial sources, ensuring high quality and specificity.

Gene-edited cells allow systematic loss-of-function studies. For example, TP53 knockout in HCT116 cells abrogates G1/S checkpoint, increasing sensitivity to DNA-damaging agents. KRAS G12D knock-in in a wild-type background confers growth factor independence and resistance to EGFR inhibitors. Such models validate candidate oncogenes and tumor suppressors identified from genomic screens.

Isogenic pairs (e.g., KRAS wild-type vs. KRAS G12D) enable high-throughput screening to identify compounds that selectively kill mutant cells. Resistance models can be generated by chronic exposure to drugs, followed by CRISPR editing of candidate resistance genes. For instance, PIK3CA mutant cells show resistance to cetuximab, and editing PIK3CA to wild-type restores sensitivity.

CRISPR screens using gene-edited libraries can identify synthetic lethal interactions. For example, in KRAS-mutant CRC, depletion of TBK1 or STK33 selectively kills mutant cells. Gene-edited models also help validate biomarkers for patient stratification, such as MSI status for immune checkpoint inhibitor response.